BrainStorm Cell Therapeutics Secures Nasdaq Compliance Extension
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a prominent biotechnology firm dedicated to developing and marketing groundbreaking autologous cellular therapies, has announced being granted a compliance extension by Nasdaq. This extension is crucial for regaining compliance with the continued listing standards of The Nasdaq Capital Market.
Compliance Plan Approval
The company presented its plan for continued listing and compliance to the Nasdaq Hearings Panel during a hearing. Following the review, the panel provided BrainStorm with a vital extension to aid in meeting the necessary criteria for compliance.
Commitment to Compliance
Chaim Lebovits, President and CEO of BrainStorm, emphasized the company's serious approach to its compliance plan. He stated their commitment to fulfilling the listed requirements is aligned with their broader operational goals, which include launching a Phase 3b ALS study for their therapy, NurOwn®, managing debt reduction strategies, and forging strategic partnerships to amplify their therapeutic pipeline.
Focus on Financial Health and Strategic Growth
BrainStorm is proactively engaged in initiatives designed to increase shareholder value while enhancing its financial health. The firm prioritizes transparency in its operations and is committed to offering updates throughout this compliance journey.
Innovative Therapy Platforms
As innovators in the biotechnology sector, BrainStorm leverages both autologous and allogeneic platforms to develop therapies targeting neurodegenerative diseases. The company holds exclusive global licenses for the NurOwn® technology platform, which is significant for producing autologous MSC-NTF cells. These cells have received Orphan Drug designation from regulatory bodies such as the U.S. FDA and EMA for treating amyotrophic lateral sclerosis (ALS).
Upcoming Clinical Trials
As part of its ongoing research, BrainStorm is preparing for a confirmatory Phase 3b trial of NurOwn for ALS, aiming to assess safety and efficacy more thoroughly. The firm’s exosome technology, which is derived from MSC-NTF cells, adds an allogeneic therapy platform to their offerings, enabling targeted delivery of therapeutic agents through customizable nano-carrier solutions.
Collaborative Initiatives and Funding Support
BrainStorm's endeavors in clinical studies have received significant backing from organizations, including the California Institute for Regenerative Medicine (CIRM) and the National MS Society (NMSS). The company remains focused on its mission to address critical neurological and respiratory health challenges through advanced medical research.
About BrainStorm Cell Therapeutics Inc
BrainStorm Cell Therapeutics Inc. stands at the forefront of developing innovative solutions for debilitating neurodegenerative conditions. With a commitment to advancing science and improving patient outcomes, BrainStorm’s research initiatives emphasize continuous learning and enhancement of their therapy platforms.
Frequently Asked Questions
What is the purpose of the compliance extension granted by Nasdaq?
The compliance extension allows BrainStorm additional time to meet Nasdaq's continued listing requirements.
How does BrainStorm plan to enhance its clinical programs?
BrainStorm aims to launch a Phase 3b ALS study for NurOwn®, reduce debt, and pursue strategic partnerships to strengthen its offerings.
What technologies does BrainStorm utilize for its therapies?
BrainStorm employs both autologous and allogeneic technology platforms, particularly focusing on MSC-NTF cells derived from the NurOwn® platform.
Who is the CEO of BrainStorm Cell Therapeutics Inc.?
Chaim Lebovits serves as the President and CEO of BrainStorm Cell Therapeutics Inc.
What designations have BrainStorm’s therapies received?
The U.S. FDA and the European Medicines Agency recognize NurOwn® cells with Orphan Drug designation for ALS treatment.
